Chelsea Therapeutics International, Ltd. (
Q4 2011 Earnings Call
March 6, 2012 4:30 pm ET
Kate McNeil - Director, IR
Simon Pedder - President and CEO
Nick Riehle - CFO
Art Hewitt - CSO
Bill Schwieterman - CMO
Keith Schmidt - VP, Marketing and Sales
Robyn Karnauskas - Deutsche Bank
Liana Moussatos - Wedbush Securities
Alan Carr - Needham & Company
Jonathan Eckard - Leerink Swann
Juan Sanchez - Ladenburg
Good day, and welcome to the Chelsea Therapeutics International fourth quarter conference call. (Operator Instructions) I would now like to introduce the host for today's conference, Ms. Kate McNeil, Director of Investor Relations.
Good afternoon and welcome to Chelsea Therapeutics fourth quarter and full year 2011 conference call. We announced our fourth quarter full year 2011 results this afternoon after the close of the U.S. financial markets and our press release can be found on our website at www.chelseatherapeutics.com.
Joining me from Chelsea Therapeutics is Dr. Simon Pedder, President and Chief Executive Officer; Mr. Nick Riehle, Chief Financial Officer; Dr. Art Hewitt, Chief Scientific Officer; Dr. Bill Schwieterman, Chief Medical Officer; and Mr. Keith Schmidt, Vice President of Marketing and Sales.
Before I turn the meeting over to Dr. Pedder, let me note that some of the remarks you'll hear today may contain forward-looking statements about the company's performance. Actual future results might differ materially from those projected in these forward-looking statements.